PA-21-259 - PHS 2021-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
PA-21-260- PHS 2021-2 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)
PA-21-262 - PHS 2021-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
PA-21-261- PHS 2021-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)
Office of The Director, National Institutes of Health (OD)
This Notice is to inform the eligible United States small business concerns of the reissuance of the Omnibus Solicitations of the NIH, CDC and FDA for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grant applications.
When reissued, these FOAs will continue to utilize the R41/R42 and R43/44 grant mechanisms. Modifications to these FOAs will be the inclusion of new and revised research priorities.
NIH, CDC, and FDA Institutes and Centers likely to participate in one or more of the FOAs include the following:
National Institutes of Health (NIH)
Centers for Disease Control (CDC)
Food and Drug Administration (FDA)
This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and appropriate projects.
The FOA is expected to be published in Summer 2022 with an expected application due date in September 2022.
The SBIR program, as established by law, is intended to meet the following goals: stimulate technological innovation in the private sector; strengthen the role of small business in meeting Federal research or research and development (R/R&D) needs; increase the commercial application of Federally-supported research results; foster and encourage participation by socially and economically disadvantaged small business concerns and women-owned business concerns in the SBIR program; and improve the return on investment from Federally-funded research for economic and social benefits to the Nation.
The STTR program is intended to stimulate a partnership of ideas and technologies between innovative small business concerns and non-profit research institutions through Federally-funded research or research and development (R/R&D). By providing awards to small businesses for cooperative R/R&D efforts with non-profit research institutions, the STTR program assists the small business and research communities by commercializing innovative technologies.
SBIR/STTR are phased programs. The main objective in SBIR/STTR Phase I is to establish the technical merit and feasibility of the proposed research and development efforts, whereas in SBIR/STTR Phase II it is to continue the R&D efforts to advance the technology toward ultimate commercialization.
An objective of the SBIR and STTR programs is to increase private sector commercialization of innovations derived from federally supported research and development. At the conclusion of an SBIR/STTR Phase II, it is expected that the small business will fully commercialize their product or technology using non-SBIR/STTR funds (either federal or non-federal).
Diversity within the NIH-supported scientific workforce fosters innovation, enhances global competitiveness, improves the quality of research and research outcomes. NIH has a commitment to supporting a sustainable and diverse biomedical research workforce. (Notice of NIH's Interest in Diversity, NOT-OD-20-031). Scientists and trainees from underrepresented backgrounds and life experiences bring different perspectives, creativity, and individual enterprise to address complex scientific problems. Fostering and encouraging participation by socially and economically disadvantaged and women-owned small businesses in technological innovation is one of the goals of the SBIR and STTR programs. (https://www.sbir.gov/sites/default/files/SBIR-STTR_Policy_Directive_2019.pdf)
NIH intends to re-issue the four Funding Opportunity Announcements (FOAs):
Applications are not being solicited at this time.
Please direct all inquiries to:
SEED (Small business Education and Entrepreneurial Development)
Office of Extramural Research